Fluvastatin XL

ApprovedSmall molecule

Novartis

Fluvastatin XL is one of 123 small molecule programs targeting Metabolic Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

122

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic SyndromeActive, not recruiting

Erectile DysfunctionActive, not recruiting

Breast CancerActive, not recruiting

HypercholesterolemiaActive, not recruiting

Metabolic SyndromeApproved

Active, not recruiting

Erectile DysfunctionPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

HypercholesterolemiaApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Fluvastatin XL

Novartis

Approved

1 2

DATROWAY

Daiichi Sankyo

Preclinical

4 3

MS Contin

Merck & Co.

Preclinical

2 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 7

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metabolic Syndrome2 trials

The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

Completed· Novartis logo

Novartis·Phase 4·NCT00664742·614 enrolled

Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome

Completed· Novartis logo

Novartis·Phase 4·NCT00385658·75 enrolled

Hypercholesterolemia1 trial

Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Completed· Novartis logo

Novartis·Phase 4·NCT01551173·436 enrolled

Breast Cancer1 trial

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

Completed·UUniversity of California, San Francisco·Phase 2·NCT00416403·35 enrolled

Erectile Dysfunction1 trial

Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors

Withdrawn·UUniversity Hospital, Saarland·Phase 3·NCT00382161·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Fluvastatin XL. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluvastatin XL compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluvastatin XL. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Fluvastatin XL

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metabolic Syndrome2 trials

Hypercholesterolemia1 trial

Breast Cancer1 trial

Erectile Dysfunction1 trial

References

Drug Info

Quick Facts

Related News